Top 8 Trials From 2021 in Breast Cancer

Debu Tripathy, MD, discusses the implications of results from the phase 3 NALA trial in patients with HER2-positive metastatic breast cancer with brain metastases.

Komal Jhaveri, MD, FACP, discusses the implications of the phase 2 TUXEDO-1 trial in patients with HER2-positive metastatic breast cancer with brain metastases.

Tiffany A. Traina, MD, discusses the implications of the phase 3 EMERALD trial in advanced estrogen receptor–positive, HER2-negative breast cancer.

Komal Jhaveri, MD, FACP, discusses the implications of data from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Leading oncologists in breast cancer share their perspectives on the biggest abstracts that were presented throughout 2021 .

Debasish Tripathy, MD, provides perspective on some of the key data sets that were presented and published in 2021 in HER2-positive breast cancer.